Trial Profile

Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 May 2026 According to AbbVie media release, the company announced ,that the European Commission (EC) has authorized an expanded label for VENCLYXTO to include use in combination with ibrutinib, this approval is supported by data from the Phase 3 GLOW and Phase 2 CAPTIVATE trials.
12 Jun 2025 Results presented in the Janssen Cilag Media Release.
19 Nov 2024 According to a Johnson & Johnson media release, results from this study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com